ADAPY - Adaptimmune Therapeutics PLC

0.015
0.005   32.667%

Share volume: 92,885
Last Updated: 03-26-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$0.01
0.00
0.49%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-25.00%
1 Month
36.36%
3 Months
-57.26%
6 Months
-66.67%
1 Year
-66.67%
2 Year
-66.67%
Key data
Stock price
$0.02
P/E Ratio 
N/A
DAY RANGE
$0.01 - $0.02
EPS 
N/A
52 WEEK RANGE
$0.00 - $0.07
52 WEEK CHANGE
-$66.67
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$145,333
AVERAGE 30 VOLUME 
$212,190
Company detail
CEO: Adrian Rawcliffe
Region: US
Website: adaptimmune.com
Employees: 490
IPO year: 2015
Issue type:
Market: OTCM
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Adaptimmune Therapeutics plc focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS)

Recent news